
Contagion® spoke to Onyema Ogbuagu, MD, who presented the week 96 results from the DISCOVER study evaluating F/TAF and F/TDF.

Contagion® spoke to Onyema Ogbuagu, MD, who presented the week 96 results from the DISCOVER study evaluating F/TAF and F/TDF.

There was a statistically significant difference in renal safety which favored F/TAF over F/TDF at Week 96.

The rate of viral suppression among US youth aged 13 to 24 with HIV (YWH) hovers between 12 and 26%, representing an important clinical and public health challenge.

A study has identified geographic and socioeconomic drivers of conscientious vaccine exemption choice in Texas.

The WHO has announced that it considers COVID-19 a pandemic.

Italy has turned to drastic measures to contain the spread of COVID-19, placing the entire country on lockdown until at least April 3.

The FDA has launched an outbreak investigation in several states concerning mushrooms which may be contaminated with Listeria monocytogenes.

With community-acquired pneumonia (CAP), the numbers tell the story.

The time is now to put in place comprehensive action plans now to monitor, detect, and respond to treatment failure on dolutegravir.

Understanding the nuances of screening and testing criteria.

HHS announced that they will purchase 500 million N95 respirators over the next 18 months.

The abstract authors report that both HIV viral load in plasma and proviral HIV DNA in CD4 cells have remained below levels of detection for up to 30 months.

Reducing barriers to care is paramount for people living with HIV and one such barrier in some countries, such as Zimbabwe, is high treatment loads that affect health system efficiency.

The state of New Jersey has confirmed its first COVID-19 death.

The last confirmed patient with Ebola was discharged from care on March 4, 2020.

Women living with HIV who are on an antiretroviral therapy regimen of dolutegravir experienced persistently higher weight postpartum compared with women on efavirenz in Botswana.

Travel history may be useful as a fifth vital sign in detecting coronavirus or any novel infectious disease.

The impact of COVID-19 has started to trickle into the sphere of conferences and large events.

“There are structural drivers that are impeding prevention and treatment among people who inject drugs,” Strathdee said in an interview with Contagion®.

The FTC and FDA have issued 7 companies warning letters for marketing fraudulent COVID-19 products.

For African men living with HIV who are not virally suppressed, community-based antiretroviral therapy (ART) significantly increased viral suppression compared with clinic-based ART.

Stay on top of coronavirus developments from March 9, 2020.

New Week 96 data from the FLAIR study indicate that once-monthly injections of cabotegravir and rilpivirine remains non-inferior and safe when compared with the daily, oral 3-drug regimen of ABC/DTG/3TC.

A team of investigators inadvertently discovered a way to preserve vaccines at room temperature for long periods of time.

A team of investigators hypothesized that prevalent syphilis infection in women with and without HIV may be a way to identify individuals who are at an elevated risk of a stillbirth over time.

Despite the high level of knowledge surrounding immediate initiation of ART, the practice is not yet the standard of care across clinics in NYC.

An international team of investigators shares 48-week results from ATLAS-2M, which tested out every other month dosing of the intramuscular injection compared with monthly dosing.

Two new papers highlight the importance of the gastrointestinal tract in symptoms and spread of coronavirus.

Investigators conducted 2 studies on intravenously administered GS-9722, 1 in HIV-negative participants and 1 in virally suppressed people with HIV.